当前位置: X-MOL 学术Int. Immunopharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma.
International Immunopharmacology ( IF 4.8 ) Pub Date : 2020-07-16 , DOI: 10.1016/j.intimp.2020.106707
Xiaohong Jin 1 , Huiwen Xie 1 , Xiaoman Liu 1 , Qiuyan Shen 2 , Ziheng Wang 3 , Haiyan Hao 4 , Yan Gu 1
Affiliation  

Background

Diffuse gliomas are the most prevalent primary brain tumors. The Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases provide evidence of the relationships between gliomas and altered molecular pathways. In glioma pathogenesis, the microenvironment has emerged as a potential indicator of tumor progression.

Methods

We investigated and confirmed the role of RELT-like 1 (RELL1) oncogene in glioblastoma and low-grade glioma by data mining large cohorts of TCGA and the CGGA. Correlations between immune cells and RELL1 were verified using the CIBERSORT algorithm.

Results

Our analysis revealed that RELL1 expression was much higher in grade-dependent glioma patients with poor prognosis. Comparable prognostic values for isocitrate dehydrogenase 1 (IDH1) and RELL1 were observed during in-depth analyses of the integrated correlations. Moreover, RELL1 was found to be associated with numerous tumor-infiltrating immune cells in glioma-affected patients.

Conclusion

We conclude that RELL1 might serve as a potential therapeutic target or prognostic marker in glioblastoma and diffuse glioma cases.

更新日期:2020-07-16
down
wechat
bug